Eli Lilly's Weight Loss Drugs Drive Big Growth

Eli Lilly, a major drug company, is having a great year. Its new drugs for weight loss and diabetes, Zepbound and Mounjaro, are selling very well. This strong performance means more money for the company.

Experts expected good results, but Eli Lilly did even better. The company sold much more than predicted. This success helped Eli Lilly raise its financial goals for the future.

The company now expects to make between $85 billion and $87 billion by 2026. This is a big jump from its earlier prediction of $82 billion to $85 billion. The demand for their new medicines drives this growth.

What does this mean for you? It shows how important these new drugs are in the health market. It also highlights Eli Lilly's strong position in developing innovative treatments. This could lead to more research and new medicines in the future.

Source: CNBC